{"name":"Deciphera Pharmaceuticals","slug":"deciphera","ticker":"DCPH","exchange":"NASDAQ","domain":"deciphera.com","description":"","hq":"Waltham, MA","founded":0,"employees":"","ceo":"","sector":"Oncology / Kinase Inhibitors","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":200000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"DCC-2036","genericName":"DCC-2036","slug":"dcc-2036","indication":"Other","status":"phase_1"},{"name":"DCC-3009","genericName":"DCC-3009","slug":"dcc-3009","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"DCC-2618","genericName":"DCC-2618","slug":"dcc-2618","indication":"Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease","status":"phase_3"}]}],"pipeline":[{"name":"DCC-2036","genericName":"DCC-2036","slug":"dcc-2036","phase":"phase_1","mechanism":"DCC-2036 is a kinase inhibitor designed to target specific enzymes involved in cancer cell growth and survival.","indications":[],"catalyst":""},{"name":"DCC-2618","genericName":"DCC-2618","slug":"dcc-2618","phase":"phase_3","mechanism":"DCC-2618 is a tyrosine kinase inhibitor that targets KIT, PDGFRA, and other receptor tyrosine kinases involved in gastrointestinal stromal tumors and other malignancies.","indications":["Gastrointestinal stromal tumor (GIST), including imatinib-resistant and sunitinib-resistant disease","Advanced systemic mastocytosis"],"catalyst":""},{"name":"DCC-3009","genericName":"DCC-3009","slug":"dcc-3009","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[],"patents":[],"drugCount":3,"phaseCounts":{"phase_1":2,"phase_3":1},"enrichmentLevel":0,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}